Professional Summary
Professional Overview
Alison McMorn is an experienced pharmaceutical executive currently serving as the Vice President of Clinical Development at AMO Pharma Limited. With over 20 years of industry expertise, she specializes in leading complex clinical programs and driving strategic initiatives that advance the development of innovative therapies.
Experience Summary
Current Role
As the Vice President of Clinical Development at AMO Pharma, Alison is responsible for overseeing all aspects of the company's clinical development activities. In this role, she has successfully managed the execution of multiple Phase I-III trials, ensuring strict adherence to regulatory guidelines and streamlining operational processes to maximize efficiencies. Alison's strategic leadership has been instrumental in advancing AMO Pharma's pipeline, contributing to the company's growing reputation as a leader in the pharmaceutical industry.
Career Progression
Prior to joining AMO Pharma, Alison held progressive roles within the pharmaceutical sector, including Director of Clinical Programs at Shire Pharmaceuticals and Clinical Program Manager at Napp Pharmaceuticals. In these positions, she demonstrated a proven track record of effectively managing cross-functional teams, optimizing clinical trial operations, and advancing drug candidates through the development pipeline. Alison's extensive experience in the industry has enabled her to develop a deep understanding of the challenges and best practices associated with clinical development.
Academic Background
Alison holds a Bachelor of Science degree in Pharmacy from the University of Cambridge, where she graduated with distinction. Her specialized training and academic achievements have equipped her with a strong foundation in pharmaceutical sciences, which she has successfully applied throughout her career.
Areas of Expertise
- Clinical trial design and management
- Regulatory compliance and strategy
- Cross-functional team leadership
- Operational efficiency and process optimization
- Strategic planning and decision-making
- Stakeholder engagement and collaboration
Professional Impact
Alison's contributions to the pharmaceutical industry have been recognized through her leadership in several high-profile clinical development initiatives. Under her guidance, AMO Pharma has achieved significant milestones, including the successful completion of a pivotal Phase III trial for a rare disease treatment and the subsequent submission of a New Drug Application to regulatory authorities. Alison's expertise and dedication have been instrumental in driving innovation and improving patient outcomes within the therapeutic areas she has worked in.
Conclusion
With her extensive experience, strategic vision, and proven track record of success, Alison McMorn is poised to continue making a significant impact in the pharmaceutical industry. As the Vice President of Clinical Development at AMO Pharma, she remains committed to advancing the company's pipeline and contributing to the development of groundbreaking therapies that address unmet medical needs.
